Dr. Gupta on the Design of the PARADIGM Study in Urothelial Cancer

Shilpa Gupta, MD, oncologist, Hematology and Medical Oncology, Cleveland Clinic, discusses the design of the PARADIGM study in locally advanced or metastatic urothelial cancer.

The PARADIGM study used qualitative interviews to assess US physician treatment decision-making and prescribing patterns of patients with locally advanced or metastatic urothelial cancer.

PARADIGM examined treatment patterns by looking at frontline therapy, maintenance therapy, prescription patterns, and barriers to using treatments for patients, Gupta explains. Interviews with medical oncologists from both community practices and academic centers painted a clearer picture about different approaches for frontline therapy, Gupta says.

The study aimed to understand how many patients are receiving treatment and what they are being administered. Though drugs have been approved for this patient population, many patients are not getting the approved drugs due to variety of barriers, Gupta concludes.